barx1 Antibody

What is BARX1 and what cellular functions does it regulate?

BARX1 is a member of the Bar subclass of homeobox transcription factors, functioning as a 226-amino acid nuclear protein primarily expressed in testis, heart, and craniofacial tissues . As a homeodomain transcription factor, BARX1 plays crucial roles in odontogenesis, craniofacial development, and stomach organogenesis . At the molecular level, BARX1 controls mesenchymal cell expression of two secreted Wnt antagonists, sFRP1 and sFRP2, which are important in gastric endoderm development preceding epithelial differentiation . During early molar development, BARX1 directs undetermined ectomesenchymal cells in the proximal jaw region to follow the pathway of multicuspid tooth development . The expression of BARX1 is positively regulated by fibroblast growth factor-8 (FGF8) and negatively regulated by bone morphogenetic protein-4 (BMP4) .

Recent research has identified BARX1 as a potential tumor suppressor in hepatocellular carcinoma (HCC), as down-regulation of BARX1 promotes HCC migration, invasion and metastasis, while up-regulation inhibits these processes . The loss of BARX1 expression represents a prognostic biomarker in human HCC, suggesting its potential clinical relevance beyond developmental biology .

What types of BARX1 antibodies are available for research applications?

Several types of BARX1 antibodies are available for research applications, varying in host species, clonality, and intended applications. The most common types include:

• Mouse monoclonal antibodies:

  • Examples include Barx1 Antibody (392.8), an IgG1 κ mouse monoclonal antibody that detects Barx1 protein of mouse, rat, and human origin

  • BARX1/2760 clone, a mouse monoclonal antibody optimized for IHC-P applications with human samples

• Rabbit polyclonal antibodies:

  • Multiple suppliers offer polyclonal BARX1 antibodies with reactivity to human samples

  • These antibodies are typically applicable for Western blotting, ELISA, and immunohistochemistry techniques

The choice between monoclonal and polyclonal antibodies depends on the specific research application, with monoclonals offering higher specificity but potentially lower sensitivity compared to polyclonal alternatives. For studies requiring consistent, reproducible results across multiple experiments, monoclonal antibodies like Barx1 Antibody (392.8) or BARX1/2760 may be preferable .

What are the validated applications for BARX1 antibodies?

BARX1 antibodies have been validated for multiple research applications, with specific validation data available for various commercial products. The primary validated applications include:

Researchers should note that even within validated applications, optimization may be necessary for specific experimental conditions, tissue types, or species . For novel applications, pilot studies with positive and negative controls are strongly recommended.

What protocols are recommended for BARX1 immunohistochemistry?

For optimal BARX1 immunohistochemistry, researchers should follow these validated protocols based on published methods:

• Sample preparation:

  • De-paraffinize FFPE sections, dehydrate, and block endogenous peroxidase activity

  • Perform antigen retrieval in a pressure cooker using citrate buffer (such as Dako S1699) at 123°C at 15 PSI for 45 seconds

• Antibody incubation:

  • For BARX1/2760 antibody: Use at 1-2 μg/ml dilution

  • For other BARX1 antibodies: Typically used at 1:100 dilution (e.g., Atlas Antibodies HPA055858)

  • Incubate with primary antibody for 45 minutes at room temperature

• Detection systems:

  • For mouse monoclonal antibodies: Use Labeled Polymer-HRP anti-mouse secondary antibody (e.g., Dako K4007)

  • For rabbit antibodies: Use Post Primary followed by Novolink Polymer Detection System (e.g., Leica RE7150-K)

  • Develop with DAB+ solution (e.g., Dako K3468) and counterstain with hematoxylin

This protocol has been validated for detecting BARX1 in human tissue samples, particularly in contexts where nuclear localization is expected due to BARX1's function as a transcription factor .

How can I perform double immunostaining with BARX1 and other markers?

Double immunostaining with BARX1 and other markers requires careful planning to avoid cross-reactivity and ensure distinct visualization of each target. Based on validated protocols, the following approach is recommended for c-KIT/BARX1 double staining:

• First marker staining (c-KIT example):

  • Incubate sections with c-KIT antibody (1:150, e.g., A4512, Dako) for 45 minutes

  • Apply AP Polymer anti-mouse secondary antibody (e.g., Ultra Vision LP, TL-125-AP)

  • Develop with Alkaline Phosphatase Red Substrate Kit (e.g., Vector SK-5105)

• Intermediate antigen retrieval:

  • Perform a second antigen retrieval in pressure cooker with citrate buffer at 123°C, 15 PSI for 45 seconds

  • This step helps expose additional epitopes without disrupting the first staining

• Second marker staining (BARX1):

  • Block with Novolink Polymer Detection Protein Block

  • Incubate with BARX1 antibody at 1:100 (e.g., HPA055858) for 45 minutes

  • Apply Post Primary and then Novolink Polymer Detection System

  • Develop with DAB+ solution and counterstain with hematoxylin

This sequential approach results in red (c-KIT) and brown (BARX1) staining, allowing for clear visualization of the relationship between the two markers. The choice of chromogens (red vs. brown) can be adjusted based on the expected localization patterns of the proteins of interest .

What are the recommended protocols for BARX1 immunoblotting?

For effective BARX1 immunoblotting, researchers should follow these validated procedures:

• Protein extraction:

  • Lyse cells in RIPA buffer containing protease inhibitor cocktail (e.g., Roche)

  • Centrifuge at 14,000 g for 10 minutes to remove genomic DNA and debris

  • Determine protein concentration using a bicinchoninic acid-based assay (BCA)

• SDS-PAGE and Western blotting:

  • Load equal amounts of protein per lane (typically 20-50 μg)

  • Separate proteins by SDS-PAGE using a 10-12% gel (optimal for the 226 amino acid BARX1 protein)

  • Transfer to nitrocellulose or PVDF membrane

• Antibody incubation:

  • Block membrane with appropriate blocking buffer (typically 5% non-fat milk or BSA)

  • Incubate with primary BARX1 antibody (1:500, e.g., Thermo Fisher Scientific PA5–68362)

  • Include loading control antibody such as ERK (1:2,000, e.g., Cell Signaling Technology #9107)

• Detection:

  • Probe with appropriate secondary antibodies (anti-mouse or anti-rabbit)

  • Detect using infrared imaging systems (e.g., Odyssey CLx, LI-COR Biosciences) or chemiluminescence

For optimal results, researchers should include positive controls (tissues or cell lines known to express BARX1) and negative controls (tissues or cell lines with low or no BARX1 expression) to validate antibody specificity and performance .

How can BARX1 antibodies be used to study BARX1's role in cancer progression?

BARX1 antibodies have become valuable tools in investigating the role of BARX1 in cancer progression, particularly in hepatocellular carcinoma (HCC) where BARX1 has been identified as having tumor suppressive properties. Researchers can employ several methodological approaches:

• Expression correlation studies:

  • Use BARX1 antibodies for immunohistochemistry on tissue microarrays containing tumor and matched normal tissues

  • Score expression levels (e.g., absent, low, moderate, high) and correlate with clinicopathological parameters

  • Analyze association between BARX1 expression and patient survival, tumor stage, or metastatic status

• Functional studies in cell lines:

  • Establish BARX1 knockdown and overexpression cell models

  • Use BARX1 antibodies to confirm knockdown/overexpression by Western blotting

  • Assess changes in cellular phenotypes (proliferation, migration, invasion)

  • Correlate these changes with BARX1 expression levels

• Mechanistic investigations:

  • Use BARX1 antibodies for chromatin immunoprecipitation (ChIP) to identify direct target genes

  • Perform co-immunoprecipitation to identify protein interaction partners

  • Investigate the effects of BARX1 expression on Wnt signaling components, given BARX1's known role in regulating Wnt antagonists

Given that loss of BARX1 expression represents a prognostic biomarker in human HCC, systematic analysis using immunohistochemistry with validated BARX1 antibodies can provide valuable clinical insights and potential stratification markers for patient management .

What approaches can be used to study BARX1's developmental functions?

BARX1's critical roles in craniofacial development, odontogenesis, and stomach organogenesis can be studied using several antibody-dependent methodological approaches:

• Spatiotemporal expression analysis:

  • Perform immunohistochemistry or immunofluorescence on developmental tissue sections

  • Use BARX1 antibodies at optimized dilutions (typically 1:100-1:300)

  • Co-stain with developmental markers to establish lineage relationships

  • Document expression patterns across different developmental stages

• Regulatory pathway analysis:

  • Investigate the effects of FGF8 (positive regulator) and BMP4 (negative regulator) on BARX1 expression

  • Treat relevant cell types or ex vivo tissue cultures with recombinant growth factors

  • Assess changes in BARX1 expression by immunoblotting or immunofluorescence

  • Quantify expression changes using image analysis software or Western blot densitometry

• Wnt signaling interactions:

  • Examine BARX1's role in regulating Wnt antagonists sFRP1 and sFRP2 during development

  • Use BARX1 antibodies alongside antibodies against Wnt pathway components

  • Perform double immunostaining to visualize spatial relationships between BARX1 and Wnt-related proteins

  • Correlate BARX1 expression with Wnt pathway activity using reporter assays

These approaches can be applied to various model systems, including mouse embryonic tissues, chick embryos, or human stem cell-derived organoids, depending on the specific developmental process under investigation .

How can I validate the specificity of BARX1 antibodies?

Validating BARX1 antibody specificity is crucial for ensuring reliable research results. A comprehensive validation strategy should include:

• Positive and negative controls:

  • Test antibodies on tissues/cells known to express BARX1 (testis, heart, craniofacial tissue)

  • Include tissues/cells with minimal BARX1 expression as negative controls

  • Use genetic models with BARX1 knockout or knockdown when available

• Western blot validation:

  • Confirm single band at expected molecular weight (~27-30 kDa for human BARX1)

  • Perform antibody pre-absorption test with recombinant BARX1 protein

  • Compare multiple BARX1 antibodies targeting different epitopes

• RNA-protein correlation:

  • Perform parallel analysis of BARX1 mRNA expression (RT-qPCR, RNA-seq)

  • Correlate protein levels (determined by antibody) with mRNA expression

  • Consistent patterns increase confidence in antibody specificity

• Additional validation approaches:

  • SDS-PAGE analysis of purified, BSA-free antibody to confirm integrity and purity

  • Comparison of staining patterns across multiple antibody dilutions

  • For monoclonal antibodies, confirmation of clone identity and isotype

When selecting commercial antibodies, researchers should prioritize those with extensive validation data, such as those with multiple validated applications (e.g., WB, ELISA, IF, IHC) as documented in product datasheets .

How do I troubleshoot weak or non-specific BARX1 immunostaining?

When encountering weak or non-specific BARX1 immunostaining, consider these methodological approaches to improve results:

• Addressing weak staining:

  • Optimize antigen retrieval: For BARX1, pressure cooker-based retrieval in citrate buffer (pH 9, 10mM Tris with 1mM EDTA) for 20 minutes has proven effective

  • Increase antibody concentration: Consider using higher concentrations (e.g., 2-5 μg/ml) while monitoring background

  • Extend incubation times: Overnight incubation at 4°C may increase sensitivity

  • Enhance detection systems: Use amplification systems like polymer-based detection or tyramide signal amplification

• Reducing non-specific background:

  • Optimize blocking: Use protein blocking reagents specifically designed for IHC (e.g., Novolink Polymer Detection Protein Block)

  • Include additional blocking steps: Consider adding avidin/biotin blocking if using biotin-based detection

  • Reduce secondary antibody concentration: Titrate to find optimal signal-to-noise ratio

  • Add detergents: Include 0.1-0.3% Triton X-100 in washing buffers to reduce hydrophobic interactions

• Protocol modifications for difficult samples:

  • For highly fixed tissues: Extend antigen retrieval time to 30-40 minutes

  • For tissues with high endogenous peroxidase: Double the peroxidase blocking step

  • For tissues with high background: Include an additional blocking step with 10% normal serum from the same species as the secondary antibody

Each modification should be tested systematically, changing one variable at a time to identify the optimal conditions for your specific sample type and antibody combination .

What controls should be included in BARX1 antibody experiments?

A robust experimental design for BARX1 antibody-based research should include the following controls:

• Antibody specificity controls:

  • Positive tissue controls: Include samples known to express BARX1 (testis, heart, craniofacial tissues)

  • Negative tissue controls: Include samples with minimal BARX1 expression

  • No primary antibody control: Process samples with all reagents except primary antibody

  • Isotype control: Use non-specific antibody of the same isotype (e.g., mouse IgG, kappa)

• Technical controls:

  • Loading controls for Western blotting: Include housekeeping proteins (e.g., ERK, GAPDH, β-actin)

  • Internal staining controls for IHC: Identify tissues within the sample that should be consistently positive or negative

  • Antibody dilution series: Perform titration experiments to determine optimal concentration

• Biological validation controls:

  • BARX1 knockdown/knockout samples: When available, include samples with genetically reduced BARX1

  • BARX1 overexpression samples: Include samples with artificially elevated BARX1 levels

  • Developmental stage controls: For developmental studies, include samples from different stages where BARX1 expression is known to change

• For double immunostaining:

  • Single staining controls: Process parallel samples with each primary antibody alone

  • Reverse chromogen controls: Swap chromogens to ensure staining patterns are consistent regardless of detection method

Comprehensive documentation of these controls increases confidence in experimental outcomes and facilitates troubleshooting if unexpected results occur.

How do I quantify BARX1 expression in immunohistochemistry?

Accurate quantification of BARX1 expression in immunohistochemistry requires systematic approaches:

• Semi-quantitative scoring methods:

  • Intensity scoring: Grade staining intensity as 0 (negative), 1+ (weak), 2+ (moderate), or 3+ (strong)

  • Percentage scoring: Estimate percentage of positive cells in defined tissue regions

  • H-score calculation: Multiply intensity score (0-3) by percentage of positive cells (0-100%) for a range of 0-300

  • Quick score: Combine intensity (0-3) and proportion scores (0-6) for a range of 0-18

• Digital image analysis approaches:

  • Use specialized software (e.g., ImageJ, QuPath, Aperio) for automated quantification

  • Define regions of interest (ROIs) in tissue samples

  • Set color thresholds to identify DAB-positive (BARX1) and hematoxylin-positive (nuclei) areas

  • Calculate nuclear BARX1 positivity as percentage of positive nuclei or average optical density

• Standardization considerations:

  • Process all samples simultaneously when possible

  • Include reference samples across multiple batches for inter-batch calibration

  • Normalize BARX1 staining to internal controls

  • Blind observers to experimental conditions during manual scoring

• Statistical analysis:

  • Calculate inter-observer and intra-observer variability for manual scoring

  • Establish correlation between manual and automated scores

  • Determine appropriate cutoff values for categorizing samples as BARX1-positive or BARX1-negative

When relating BARX1 expression to functional outcomes, consider the biological relevance of nuclear versus cytoplasmic staining, given BARX1's role as a transcription factor primarily active in the nucleus .

How can BARX1 antibodies contribute to understanding transcriptional networks?

BARX1 antibodies can serve as powerful tools for deciphering the transcriptional networks regulated by this homeodomain factor through several methodological approaches:

• Chromatin immunoprecipitation (ChIP) applications:

  • Use BARX1 antibodies to immunoprecipitate chromatin fragments bound by BARX1

  • Couple with sequencing (ChIP-seq) or qPCR (ChIP-qPCR) to identify genomic binding sites

  • Map BARX1 binding sites to gene regulatory regions

  • Combine with transcriptomic data to correlate binding with gene expression changes

• Protein-protein interaction studies:

  • Employ BARX1 antibodies for co-immunoprecipitation to identify transcriptional cofactors

  • Validate interactions through reciprocal co-IP experiments

  • Perform proximity ligation assays (PLA) to visualize protein interactions in situ

  • Map interaction domains through deletion mutant analysis

• Transcriptional program characterization:

  • Use BARX1 antibodies alongside HAND1 antibodies to study divergent transcriptional programs

  • Perform sequential ChIP (re-ChIP) to identify genomic regions co-occupied by multiple factors

  • Correlate BARX1 binding with epigenetic modifications using sequential immunoprecipitation

These approaches can reveal how BARX1 coordinates with other transcription factors to regulate developmental processes and how dysregulation of these networks may contribute to pathological conditions like hepatocellular carcinoma .

What is the potential of BARX1 as a diagnostic or prognostic biomarker?

The emerging role of BARX1 as a potential biomarker, particularly in cancer, warrants systematic investigation using validated antibodies:

• Prognostic value assessment:

  • Perform BARX1 immunohistochemistry on tissue microarrays from patient cohorts with long-term follow-up

  • Correlate BARX1 expression levels with clinical outcomes (survival, recurrence, metastasis)

  • Down-regulation of BARX1 has been associated with HCC migration, invasion, and metastasis

  • Loss of BARX1 expression represents a potential prognostic biomarker in human HCC

• Diagnostic application development:

  • Evaluate BARX1 expression across tumor types and stages using standardized IHC protocols

  • Determine sensitivity and specificity of BARX1 as a diagnostic marker

  • Develop scoring algorithms that combine BARX1 with other diagnostic markers

  • Validate in independent patient cohorts

• Therapeutic response prediction:

  • Assess whether BARX1 expression correlates with response to specific therapies

  • Monitor changes in BARX1 levels during treatment

  • Investigate whether BARX1-directed therapies could be developed based on its tumor suppressive properties in HCC

• Technical considerations for biomarker development:

  • Standardize immunohistochemical protocols across laboratories

  • Establish reference standards for BARX1 positivity

  • Develop quality control measures for BARX1 antibody lot-to-lot consistency

  • Consider digital pathology approaches for reproducible quantification

The translation of BARX1 from a developmental factor to a clinically relevant biomarker requires rigorous validation across multiple patient cohorts and standardization of detection methods, with BARX1 antibodies serving as the critical reagents in this process .